Please assess the completion status of the following clinical trial:

Trial Title: Interferon ß-1b Treatment by Cyclical Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients affected by remitting Multiple Sclerosis who had at least a relapse in the last year of the disease.~* Satisfying general clinical conditions according to the researcher. Adequate hepatic function. Capacity to use adequate contraceptive techniques during the study.~Exclusion Criteria:~* Any other disease that might better explain signs and symptoms of the patient.~* Any other disability condition that might interfere with the clinical evolution.~* History of hypersensitivity to natural or recombinant interferon or to human albumin.~* Clinically significant heart diseases and not controlled like dysrhythmias, angina pectoris or congestive heart failure.~* Not adequately controlled epilepsy.~* Inability, according to the examining commission, to grant a complete compliance with the protocol requirements for the whole study.~* Previous therapies modifying the disease course in the last six months.~* Steroid therapies in the last 3 months.~* Pregnancy, lactation, serological positivity to the pregnancy test during the screening period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- interferon beta cyclical administration (Type: EXPERIMENTAL): Interferon ß-1b Treatment by Cyclical Administration
- Interferon ß-1b Treatment (Type: ACTIVE_COMPARATOR): Interferon ß-1b Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).